ArticleInvestigational new drugs2025

First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma.

Melissa Johnson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.